TMCnet News
Investigators Dose First Patient in Phase 1 Study of Treos Bio's PolyPEPI™ Precision Cancer Vaccine for Patients with Metastatic Colorectal CancerSAN FRANCISCO and LONDON, May 14, 2018 (GLOBE NEWSWIRE) -- Treos Bio Limited, an immuno-oncology company developing next-generation, off-the-shelf precision cancer vaccines coupled with companion diagnostics, today said investigators dosed the first patient in its Phase 1 trial of PolyPEPI™ 1018, the company’s investigational precision cancer vaccine for patients with metastatic colorectal cancer (mCRC). The phase 1 trial is investigating the safety, tolerability, and immunogenicity of the PolyPEPI 1018 CRC Vaccine as an add-on treatment to the standard-of-care maintenance therapy in patients with metastatic colorectal cancer. Vaccine induced T cell immune responses and tumor-infiltrating lymphocytes will be determined by bioassays and the correlation with the predicted T cell immune responses will also be assessed. Mayo Clinic is serving as the only U.S. site for the study. Despite advances made in therapies to treat colorectal cancer, metastatic colorectal cancer continues to be poorly addressed by available therapies and is today the second leading cause of cancer death in the United States. “While Treos has made great progress and we are proud to achieve this milestone of dosing the first patient in this first-in-man study of our precision cancer vaccine, we feel the urgency of patients with metastatic colorectal cancer in search of better therapeutic options,” said Dr. Menghis Bairu, Executive Chairman of Treos. A total of 10 adult patients between the ages of 18 and 75, who have experienced either a partial response or stable disease during first-line treatment with a systemic chemotherapy regimen and one biological therapy regimen, are being enrolled in the study. Patients interested in participating in the study can find a fuller description of the enrollment criteria o the ClinicalTrials.gov website [ClinicalTrials.gov Identifier: NCT03391232]. “Treos has long worked to understand how to stimulate the human immune system to destroy tumor cells without attacking healthy cells,” said Franco Lori, M.D, Ph.D., Chief Medical Officer of Treos Bio. “As we treat the first patient in this study of our off-the-shelf, precision cancer vaccine, it moves us one step closer to addressing an unmet need of patients and combatting this deadly disease.” About PolyPEPI™ 1018 CRC Vaccine About Colorectal Cancer About Treos Bio, Ltd. Treos Bio has completed preclinical development of additional members of the PolyPEPI cancer vaccine family with companion diagnostics to select likely responders. These patient specific off-the-shelf vaccines are designed for a general population of patients with ovarian-, breast-, lung cancers, glioma, melanoma, and leukemia. Treos Bio patient focused vaccine design also supports the development of vaccines for single individuals and a population of individuals with a specific genetic background, including specific vaccines most effective in ethnic populations. More information can be found at www.treosbio.com. Contact |